OverviewSuggest Edit

BioScrip® is a leading provider in comprehensive, cost-effective pharmaceutical and home care solutions. Our goal is to partner with patients, physicians, healthcare payors, government agencies and pharmaceutical manufacturers to provide access to infusible medications and management solutions that optimize outcomes for chronic and other complex healthcare conditions. At BioScrip, our patients receive personalized, safe, effective and convenient infusion therapies to help improve quality of life. Our team of professionals assist each patient in every step of their office or home infusion experience.
TypePublic
HQDenver, US
Websitebioscrip.com
Employee Ratings2.7

Latest Updates

Employees (est.) (Dec 2018)1,657(-4%)
Job Openings278
Revenue (FY, 2018)$708.9 M(-13%)
Share Price (Jun 2019)$2.2 (+2%)

Key People/Management at BioScrip

Richard M. Smith

Richard M. Smith

President & CEO

BioScrip Office Locations

BioScrip has offices in Denver, Charleston, Norfolk, Ashland and in 59 other locations
Denver, US (HQ)
1600 Broadway #950
Albany, US
2206 Dawson Rd Suite B
Alexandria, US
1503 Wimbledon Blvd
Annandale, US
3289 Woodburn Rd #290
Ashland, US
305 Ashcake Rd Suite G
Augusta, US
River Place Condominiums, 1 7th St #107
Show all (64)

BioScrip Financials and Metrics

BioScrip Revenue

BioScrip's revenue was reported to be $708.90 m in FY, 2018
USD

Revenue (Q2, 2019)

191.5m

Gross profit (Q2, 2019)

64.7m

Gross profit margin (Q2, 2019), %

33.8%

Net income (Q2, 2019)

(15.7m)

EBIT (Q2, 2019)

6.9m

Market capitalization (10-Jun-2019)

282.0m

Closing stock price (10-Jun-2019)

2.2

Cash (30-Jun-2019)

14.4m

EV

792.9m
BioScrip's current market capitalization is $282 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

842.2m984.1m982.2m935.6m817.2m708.9m

Revenue growth, %

17%0%(5%)

Cost of goods sold

721.3m670.0m547.9m465.9m

Gross profit

260.9m265.6m269.2m243.0m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018

Cash

15.6m9.6m39.5m14.5m

Accounts Receivable

114.9m

Inventories

43.0m36.2m38.0m26.7m

Current Assets

187.0m176.1m187.7m174.7m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Cash

9.3m1.5m23.2m1.2m29.4m8.1m51.4m2.8m16.0m40.5m33.0m30.4m20.8m18.9m5.7m14.4m

Accounts Receivable

120.8m118.1m

Inventories

30.3m34.8m34.5m33.8m41.9m42.4m26.9m29.1m32.4m33.4m30.5m28.8m27.8m41.5m25.3m23.1m27.5m27.8m

Current Assets

222.1m251.3m238.8m215.6m212.4m185.4m199.4m158.8m199.0m159.4m176.0m190.5m170.2m176.0m156.6m171.9m171.1m177.6m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(299.7m)(41.5m)(64.2m)(51.7m)

Depreciation and Amortization

22.7m21.6m27.7m23.6m

Inventories

(5.8m)10.0m(2.5m)11.4m

Accounts Payable

(24.1m)(20.5m)689.0k1.1m
USDY, 2019

EV/EBIT

432.1 x

EV/CFO

-759.3 x

Financial Leverage

-3.4 x
Show all financial metrics

BioScrip Online and Social Media Presence

Embed Graph

BioScrip News and Updates

Option Care and BioScrip Complete Merger to Form Option Care Health

Largest Independent Home and Alternate Site Infusion Provider Establishes the Standard of Care Across the United States Through Its Clinical Leadership and Technology-Enabled Patient-Centered Model.read more

BioScrip Announces Shareholder Approval of Merger with Option Care

DENVER, Aug. 02, 2019 (GLOBE NEWSWIRE) -- BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the “Company”), the largest independent national provider of infusion and home care management solutions, today announced that its stockholders approved the proposals that are conditions to the proposed merger w…

BioScrip Reports First Quarter 2019 Financial Results

DENVER, May 02, 2019 (GLOBE NEWSWIRE) -- BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions, today announced its first quarter 2019 financial results.                     

BioScrip, Inc. Provides Merger Update

DENVER, April 23, 2019 (GLOBE NEWSWIRE) -- BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions, today provided an update on its proposed merger with Option Care Enterprises, Inc. (“Option Care”).

BioScrip Reports Fourth Quarter and Full Year 2018 Financial Results

DENVER, March 15, 2019 (GLOBE NEWSWIRE) -- BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions, today announced its fourth quarter and full year 2018 financial results.                                …

Home and Alternate Site Infusion Therapy Providers BioScrip and Option Care to Merge

Creates a Leading Independent Provider of Home and Alternate Site Infusion Services with Deep Clinical Expertise and Broad Therapy Portfolio
Show more

BioScrip Frequently Asked Questions

  • Who are BioScrip key executives?

    BioScrip's key executives are Richard M. Smith.

  • How many employees does BioScrip have?

    BioScrip has 1,657 employees.

  • What is BioScrip revenue?

    Latest BioScrip annual revenue is $708.9 m.

  • What is BioScrip revenue per employee?

    Latest BioScrip revenue per employee is $427.8 k.

  • Who are BioScrip competitors?

    Competitors of BioScrip include Horizon Pharma, BioDelivery Sciences International and Perrigo.

  • Where is BioScrip headquarters?

    BioScrip headquarters is located at 1600 Broadway #950, Denver.

  • Where are BioScrip offices?

    BioScrip has offices in Denver, Charleston, Norfolk, Ashland and in 59 other locations.

  • How many offices does BioScrip have?

    BioScrip has 64 offices.